Prostate Cancer: Precancerous Conditions of The Prostate

Prostate Cancer: Precancerous Conditions of The Prostate

Precancerous conditions of the prostate are those that have the potential to develop into prostate cancer. With a precancerous condition, certain abnormal changes have occurred within the cells of the prostate. Often times because of these abnormal changes a precancerous condition has the potential to develop into prostate cancer. The three most common precancerous conditions of the prostate are:

  • prostatic intraepithelial neoplasia (PIN)
  • proliferative inflammatory atrophy (PIA)
  • atypical small acinar proliferation (ASAP)

Prostatic intraepithelial neoplasia (PIN)

Prostatic intraepithelial neoplasia (PIN) is a condition in which some of the prostate’s epithelial cells appear abnormal when examined under a microscope and is widely acknowledged as a precancerous condition of the prostate gland. PIN can occur in various areas of the prostate but is most often found in the peripheral zone of the prostate where cancer is prone to developing. PIN is primarily categorized as either low-grade or high-grade but only high-grade PIN is considered a precancerous condition.

If PIN is identified as being high-grade and present within several areas of the prostate, preventative treatment may be administered. Although not all high-grade PIN sites will necessarily develop into prostate cancer during a man’s lifetime.

Proliferative inflammatory atrophy (PIA)

This particular condition is characterized by very small abnormal cells that divide rapidly in areas of the prostate where chronic inflammation is present. PIA is not cancer, but past research has suggested that PIA is associated with an increased risk of developing into high-grade prostatic intraepithelial neoplasia (PIN) or prostate cancer.

Atypical small acinar proliferation (ASAP)

ASAP is a term used to describe unusual looking cells when no other diagnosis is clear. In ASAP, the cells appear as if they may be cancerous when examined under a microscope, but often there are too few of them to be certain. ASAP is also found in only about 2% of biopsies and patients with an initial finding have up to a 60% increased chance of developing prostate cancer.

Leave a Reply

Your email address will not be published. Required fields are marked *

David Samadi Headshot

Dr. David Samadi M.D.


Dr. David Samadi is a board certified urologic oncologist trained in open and traditional and laparoscopic surgery and is an expert in robotic prostate surgery. He is Chairman of Urology, and Chief of Robotic Surgery at Lenox Hill Hospital.

Dr. David Samadi is also part of the Fox News Medical A Team as a medical correspondent and the Chief Medical Correspondent for am970 in New York City. He has dedicated his distinguished career to the early detection, diagnosis and treatment of prostate cancer and is considered one of the most prominent surgeons in his field.

FoundationLogo

For more comprehensive information about prostate cancer, detecting prostate cancer, how to live with prostate cancer, and how to help support the fight against prostate cancer, please visit:
Samadi Robotics Foundation

ProstateCancer911Logo

For more up to date prostate cancer news, please visit: Prostate Cancer 911

RoboticOncology

To learn more about Dr. David Samadi and his practice, visit: Robotic Oncology

Translate »